KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials.

Sven Becker, Marie-Madeleine Dolmans, Francisco Carmona Herrera, Felice Petraglia, Stefan P Renner, Raluca Ionescu-Ittu, Julien St-Pierre, Mitra Boolell, Elke Bestel, Satoshi Hori, Jacques Donnez

BJOG 132(9) 1297-1306

PMID40326221
PMCIDPMC12232536
DOI10.1111/1471-0528.18190
发表日期2025-05-06
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram。
摘要

摘要

OBJECTIVE: Among women with uterine fibroids (UFs), we assess the extent to which the linzagolix effect on pain alleviation is explained by its effect on reducing heavy menstrual bleeding (HMB) and fibroid volume (FV). DESIGN: Post hoc analysis on the pooled data from two randomised double-blind placebo-controlled phase 3 trials. SETTING: 94 sites in the US (PRIMROSE 1 trial) and 95 sites in Europe/US (PRIMROSE 2 trial). POPULATION: Women aged ≥ 18 years with ultrasound-confirmed UFs and HMB (n = 1012). METHODS: Participants were randomised to linzagolix (100 mg and 200 mg, with and without hormonal add-back therapy) versus placebo. A post hoc mediation analysis was conducted on the pooled PRIMROSE 1 and PRIMROSE 2 data. The effect of linzagolix versus placebo on pain reduction was divided into three components (effect explained by HMB reduction associated with linzagolix, FV reduction associated with linzagolix, and remaining [not yet explained] treatment effect), with proportions of each component reported. MAIN OUTCOME MEASURES: The mediation analysis outcome was clinically significant pain reduction, defined as a change of ≥ 2 pain categories from baseline to Week 24 using the Numeric Rating Scale (pain categories: no pain (0), and mild (1-3), moderate (4-6), severe pain (7-10)). RESULTS: In the mediation analysis, 28%-51% (depending on treatment arm) of linzagolix effect on pain reduction was explained by its effect on HMB reduction, while 2%-8% was explained by its effect on FV reduction. The residual proportion ranged between 44% and 67%, depending on treatment arm, and was statistically significant only in the linzagolix 200 mg without add-back therapy arm (p = 0.002). CONCLUSIONS: This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. Further research is needed to identify additional mediating factors. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03070899 and NCT03070951.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Hypothesized conceptual framework for the mediation analysis. FV, Fibroid volume; HMB, heavy menstrual bleeding; MBL, menstrual blood loss; NRS, numeric rating scale.
非 KM Figure